ASCO 2025 | Phase I/II trial of BNT142, an mRNA encoded bsAb, in CLDN6+ solid tumors
Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses initial findings from the Phase I/II BNT142-01 trial (NCT05262530) of BNT142, an mRNA-encoded bispecific antibody (bsAb) targeting CLDN6 and CD3, in patients with CLDN6-positive advanced solid tumors. The study demonstrated a manageable safety profile and encouraging early efficacy, particularly in ovarian cancer, where partial responses were observed. Adverse events were mostly low grade, with dose-related cytokine activity. These results provide first-in-human clinical proof-of-concept for mRNA-based bispecific antibody therapy in solid tumors. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
